

# Product Datasheet

## PKN3 Antibody - BSA Free

### NBP1-30102

Unit Size: 100 ul

Store at 4C. Do not freeze.

[www.novusbio.com](http://www.novusbio.com)



[technical@novusbio.com](mailto:technical@novusbio.com)

**Reviews: 2 Publications: 6**

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:  
[www.novusbio.com/NBP1-30102](http://www.novusbio.com/NBP1-30102)

Updated 2/21/2025 v.20.1

**Earn rewards for product reviews and publications.**

Submit a publication at [www.novusbio.com/publications](http://www.novusbio.com/publications)

Submit a review at [www.novusbio.com/reviews/destination/NBP1-30102](http://www.novusbio.com/reviews/destination/NBP1-30102)



**NBP1-30102**

PKN3 Antibody - BSA Free

**Product Information**

<b>Unit Size</b>	100 ul
<b>Concentration</b>	1.0 mg/ml
<b>Storage</b>	Store at 4C. Do not freeze.
<b>Clonality</b>	Polyclonal
<b>Preservative</b>	0.09% Sodium Azide
<b>Isotype</b>	IgG
<b>Purity</b>	Immunogen affinity purified
<b>Buffer</b>	Tris-Citrate/Phosphate (pH 7.0 - 8.0)
<b>Target Molecular Weight</b>	99 kDa

**Product Description**


<b>Host</b>	Rabbit
<b>Gene ID</b>	29941
<b>Gene Symbol</b>	PKN3
<b>Species</b>	Human, Mouse
<b>Reactivity Notes</b>	Mouse reactivity reported in scientific literature (PMID: 30422386).
<b>Immunogen</b>	maps to a region between residue 225 and 275 of human protein kinase N3 using the numbering given in entry NP_037487.2

**Product Application Details**

<b>Applications</b>	Western Blot, Immunoprecipitation (Negative), Knockout Validated
<b>Recommended Dilutions</b>	Western Blot 1:2000-1:10000, Immunoprecipitation (Negative), Knockout Validated Reactivity validation reported in (PMID: 30518210)


**Images**

Western Blot: PKN3 Antibody [NBP1-30102] - Whole cell lysate from HeLa (5, 15 and 50 ug) and 293T (T; 50 ug) cells. Antibody used at 0.1 ug/ml.







**Western Blot: PKN3 Antibody [NBP1-30102] - Effect of siRNA-mediated disruption of PRK1, PRK2 & PRK3 expression on TP agonist-induced proliferation & migration of PC-3 cells** Panels A-D. PC-3 cells were transfected for 48 hr with 30 nM siRNAPRK1, siRNAPRK2, siRNAPRK3 or, as controls, with a scrambled siRNA (siRNAControl) prior to stimulation with U46619 (10 nM) or vehicle (0.0001% EtOH) for the indicated time specific to the assay, where non-transfected cells served as a reference. Panel A: For analysis of proliferation, 72 hr post-siRNA transfection PC-3 cells were stimulated for 48 hr with U46619 (10 nM) or vehicle (0.0001% EtOH). Panel B: For analysis of colony formation, 48 hr post-siRNA transfection PC-3 cells were stimulated with U46619 (10 nM) or vehicle (0.0001% EtOH) in soft agar & assessed 10 day post-treatment for colony formation. Panel C: For analysis of migration, 72 hr post-siRNA transfection PC-3 cells were stimulated for 8 hr with U46619 (10 nM) or vehicle (0.0001% EtOH). In Panels A-C, the bar charts show mean relative levels of PC-3 cell proliferation, colony formation & migration ( $\pm$  SEM,  $n \geq 3$ ), where levels in the vehicle-treated cells are assigned a value of 100%. The asterisks indicate where U46619-stimulation resulted in significant increases in proliferation, colony formation or migration by PC-3 cells compared to vehicle-treated cells, where \*\* & \*\*\* indicates  $p < 0.01$  &  $p < 0.001$ , respectively. Panel D: Validation of the specificity & sustained siRNA-mediated disruption of PRK1, PRK2 & PRK3 expression was confirmed by immunoblot analysis of whole cell lysates (20  $\mu$ g/lane) with the respective anti-PRK1/2/3 or, to validate protein loading, with anti-HDJ2 antisera where analysis was carried out 3 & 6 day post-transfection. Data  $n \geq 3$ . Image collected & cropped by CiteAb from the following publication (<https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.4664>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




**Western Blot: PKN3 Antibody [NBP1-30102] - Association of PRK1 & PRK2 with TP $\alpha$  & TP $\beta$  in prostate PC-3 cells** Panel A. PC-3 cells were immunoprecipitated with anti-TP $\alpha$ , anti-TP $\beta$  or, as controls, with the pre-immune (IgG) sera. Thereafter, immunoprecipitates (upper panels) or equivalent aliquots of whole cell lysates (20  $\mu$ g/lane, lower panels) were immunoblotted (IB) with anti-PRK1, anti-PRK2 or anti-PRK3 antisera. The relative positions of the molecular size markers (kDa) are indicated to the left of the panels. Data shown are representative of at least three independent experiments ( $n \geq 3$ ). Panel B. PC-3 cells were incubated with U46619 (1  $\mu$ M; 0–60 min) prior to immunoprecipitation with anti-TP $\alpha$ , anti-TP $\beta$  or, as controls, with the pre-immune (IgG) sera. Thereafter, immunoprecipitates (upper panels) or equivalent aliquots of whole cell lysates (20  $\mu$ g/lane, lower panels) were IB with anti-PRK1, anti-PRK2 or anti-PRK3 antisera. Data  $n \geq 3$ . Panel C. Bar charts show the mean relative levels of PRK1 or PRK2 associated with the anti-TP $\alpha$  or anti-TP $\beta$  immunoprecipitates, as determined by quantitative densitometry ( $\pm$  SEM), where levels associated with the respective immunoprecipitates in the absence of agonist are expressed as 1. The asterisks indicate where U46619 stimulation resulted in significant changes in complex-associated PRK1 or PRK2, where \* & \*\* indicate  $p < 0.05$  &  $p < 0.01$ , respectively. Image collected & cropped by CiteAb from the following publication (<https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.4664>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



**Western Blot: PKN3 Antibody [NBP1-30102]** - PKN3 activity is important for stress fibers formation & is stimulated by the expression of p130Cas. (A) p130Cas<sup>-/-</sup>-MEFs growing on FN-coated cover slips were co-transfected by GFP-p130Cas & mCherry-PKN3 fusion variant (WT, mPR, KD) or mCherry. After 48 h, cells were fixed & imaged by Leica TCS SP2 microscope (63×/1.45 oil objective). Stress fibers were visualized by Phalloidin (405) & focal adhesions by anti-Paxillin staining (2nd 633). Representative images are shown. Scale bars represent 20  $\mu$ m. (B) p130Cas<sup>-/-</sup>-MEFs or p130Cas<sup>-/-</sup>-MEFs re-expressing p130Cas or transfected by GFP-fused p130Cas variants (WT, YE, dCCH) were lysed in RIPA buffer, blotted to nitrocellulose membrane, & analyzed for endogenous PKN3 activity by antibody anti-phosphoThr849 of PKN3 (pT849 PKN3). Expression of p130Cas mutants was verified by anti-p130Cas antibody & loading by anti-PKN3 & anti-actin antibody. (C) Densitometric quantification of PKN3 activity (pT849 PKN3 phosphorylation). The effect of p130Cas re-expression on PKN3 T849 phosphorylation was analyzed separately from the effect of transfected p130Cas mutants (indicated by a dotted line). Error bars indicate means  $\pm$  SD from three independent experiments (four experiments for the left part). Statistical significance was evaluated by one-way repeated ANOVA followed by Turkey's post hoc test (\*P < 0.05; \*\*P < 0.01). (D) Lysates or (E) immunoprecipitates (by Flag sepharose) from p130Cas<sup>-/-</sup>-MEFs re-expressing p130Cas & overexpressing PKN3 variants (WT, mPR, KD) were immunoblotted by anti-PKN3, anti-pT849 PKN3, & anti-Akt antibodies (loading control). Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/30422386>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




**Immunocytochemistry/ Immunofluorescence: PKN3 Antibody [NBP1-30102]** - PKN3 activity is important for stress fibers formation & is stimulated by the expression of p130Cas. (A) p130Cas<sup>-/-</sup>-MEFs growing on FN-coated cover slips were co-transfected by GFP-p130Cas & mCherry-PKN3 fusion variant (WT, mPR, KD) or mCherry. After 48 h, cells were fixed & imaged by Leica TCS SP2 microscope (63×/1.45 oil objective). Stress fibers were visualized by Phalloidin (405) & focal adhesions by anti-Paxillin staining (2nd 633). Representative images are shown. Scale bars represent 20  $\mu$ m. (B) p130Cas<sup>-/-</sup>-MEFs or p130Cas<sup>-/-</sup>-MEFs re-expressing p130Cas or transfected by GFP-fused p130Cas variants (WT, YE, dCCH) were lysed in RIPA buffer, blotted to nitrocellulose membrane, & analyzed for endogenous PKN3 activity by antibody anti-phosphoThr849 of PKN3 (pT849 PKN3). Expression of p130Cas mutants was verified by anti-p130Cas antibody & loading by anti-PKN3 & anti-actin antibody. (C) Densitometric quantification of PKN3 activity (pT849 PKN3 phosphorylation). The effect of p130Cas re-expression on PKN3 T849 phosphorylation was analyzed separately from the effect of transfected p130Cas mutants (indicated by a dotted line). Error bars indicate means  $\pm$  SD from three independent experiments (four experiments for the left part). Statistical significance was evaluated by one-way repeated ANOVA followed by Turkey's post hoc test (\*P < 0.05; \*\*P < 0.01). (D) Lysates or (E) immunoprecipitates (by Flag sepharose) from p130Cas<sup>-/-</sup>-MEFs re-expressing p130Cas & overexpressing PKN3 variants (WT, mPR, KD) were immunoblotted by anti-PKN3, anti-pT849 PKN3, & anti-Akt antibodies (loading control). Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/30422386>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.







Western Blot: PKN3 Antibody [NBP1-30102] - PKN3 overexpression regulates growth of MEFs, & this effect requires PKN3–p130Cas interaction. (A) Immunoblotted lysates from MEFs p130Cas<sup>-/-</sup> or MEFs p130Cas<sup>-/-</sup> re<sup>+</sup>expressing p130Cas (p130Cas<sup>+</sup>) treated by Doxycycline (Dox) to induce expression of mCherry<sup>+</sup>PKN3 or mCherry alone. p130Cas presence detected by anti<sup>+</sup>p130Cas antibody & mCherry epitope by anti<sup>+</sup>mCherry antibody. (B) Dynamics of mCherry<sup>+</sup>PKN3 expression after supplementation w/ Dox shown by immunoblot w/ anti<sup>+</sup>mCherry antibody. (C–E) Effect of induced mCherry<sup>+</sup>PKN3 expression on cell growth. Representative graphs showing growth of MEFs p130Cas<sup>-/-</sup> re<sup>+</sup>expressing p130Cas (p130Cas<sup>+</sup>) (C) or MEFs p130Cas<sup>-/-</sup> (D) measured in real<sup>+</sup>time using xCELLigence RTCA (real<sup>+</sup>time cell analysis) system instrument. (E) Quantification of cell growth change induced by mCherry<sup>+</sup>PKN3 expression ('-' indicates inducible mCherry expression used as negative control). Slope ratios reflecting cell growth calculated from log growth phase of cell growth (indicated by dotted lines; see C & D). (F) Immunoblotted lysates from MEFs p130Cas<sup>-/-</sup> re<sup>+</sup>expressing p130Cas (p130Cas<sup>+</sup>) treated or not treated by Dox which induced expression of Flag<sup>+</sup>fused PKN3 variants (WT, mPR, KD, empty vector). Stimulated overexpression of PKN3 detected by anti<sup>+</sup>PKN3 antibody & its activity by antibody anti<sup>+</sup>pT849 PKN3. (G) Quantification of cell growth change stimulated by Dox<sup>+</sup>inducible expression of Flag<sup>+</sup>fused PKN3 variants (WT, mPR, KD) in MEFs p130Cas<sup>-/-</sup> re<sup>+</sup>expressing p130Cas (p130Cas<sup>+</sup>). All error bars indicate means  $\pm$  SD calculated from 3 to 5 independent experiments (each in triplicates). Statistical significance always calculated between induced & noninduced cells & evaluated by one<sup>+</sup>way repeated ANOVA followed by Turkey post hoc test (\*\*P < 0.001). Image collected & cropped by CiteAb from following publication (<https://pubmed.ncbi.nlm.nih.gov/30422386>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



## Publications

Aine G O'Sullivan, Eamon P Mulvaney, B Therese Kinsella Regulation of protein kinase C-related kinase (PRK) signalling by the TP $\alpha$  and TP $\beta$  isoforms of the human thromboxane A 2 receptor: Implications for thromboxane- and androgen- dependent neoplastic and epigenetic responses in prostate cancer. *Biochimica et biophysica acta. Molecular basis of disease* 2018-11-19 [PMID: 28108419]

Arang N, Lubrano S, Ceribelli M et al. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma Cell reports. *Medicine* 2023-10-13 [PMID: 37858338] (WB, Human)

Browne CM, Jiang B, Ficarro SB et al. A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification J. Am. Chem. Soc. 2019-01-09 [PMID: 30518210] (KO, WB, Human)

Gemperle J, Dibus M, Koudelkova L et al. The interaction of p130Cas with PKN3 promotes malignant growth Mol Oncol. [PMID: 30422386] (WB, Mouse)

O'Sullivan AG, Mulvaney EP, Hyland PB, Kinsella BT. Protein kinase C-related kinase 1 and 2 play an essential role in thromboxane-mediated neoplastic responses in prostate cancer. *Oncotarget* 2015-09-22 [PMID: 26296974]

Collazos A, Michael N, Whelan RD et al. Site recognition and substrate screens for PKN family proteins. *Biochem J*;438(3):535-43. 2011-09-15 [PMID: 21749319]



### **Novus Biologicals USA**

10730 E. Briarwood Avenue  
Centennial, CO 80112  
USA  
Phone: 303.730.1950  
Toll Free: 1.888.506.6887  
Fax: 303.730.1966  
nb-customerservice@bio-techne.com

### **Bio-Techne Canada**

21 Canmotor Ave  
Toronto, ON M8Z 4E6  
Canada  
Phone: 905.827.6400  
Toll Free: 855.668.8722  
Fax: 905.827.6402  
canada.inquires@bio-techne.com

### **Bio-Techne Ltd**

19 Barton Lane  
Abingdon Science Park  
Abingdon, OX14 3NB, United Kingdom  
Phone: (44) (0) 1235 529449  
Free Phone: 0800 37 34 15  
Fax: (44) (0) 1235 533420  
info.EMEA@bio-techne.com

### **General Contact Information**

www.novusbio.com  
Technical Support: nb-technical@bio-techne.com  
Orders: nb-customerservice@bio-techne.com  
General: novus@novusbio.com

### **Products Related to NBP1-30102**

---

HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control
NBP2-33444PEP	PKN3 Recombinant Protein Antigen

---

### **Limitations**

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit [www.novusbio.com/guarantee](http://www.novusbio.com/guarantee)

Earn gift cards/discounts by submitting a review: [www.novusbio.com/reviews/submit/NBP1-30102](http://www.novusbio.com/reviews/submit/NBP1-30102)

Earn gift cards/discounts by submitting a publication using this product:  
[www.novusbio.com/publications](http://www.novusbio.com/publications)

